Please ensure Javascript is enabled for purposes of website accessibility

Why This Little Stock Soared 83% in June

By Todd Campbell – Jul 9, 2016 at 6:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Favorable guidance for the use of Exact Sciences' colon cancer screening test has sparked investor optimism.

Image source: Exact Sciences.

What:  Following the release of new guidance for colon cancer screening issued by the U.S. Preventative Services Task Force (USPSTF), shares in Exact Sciences (EXAS -0.75%) skyrocketed by 83.4% last month, according to S&P Global Market Intelligence.

So what: Until now, use of Exact Sciences' Cologuard has been limited by guidelines that favored other colon cancer screening methods, such as fecal immunochemical tests (FIT) and colonoscopy. Although colon cancer screening is recommended for tens of millions of Americans over age 50, Exact Sciences completed just 104,000 Cologuard tests in 2015.

Clearly, Exact Sciences has only scratched the surface of its addressable patient population, and because of that, investors cheered news that new USPSTF guidelines no longer favor other screening methods over Cologuard. Leveling the playing field for Cologuard removes roadblocks that could have been keeping doctors from prescribing it and payers from paying for it. 

Importantly, a bigger embrace by doctors and insurers could lead to significantly more cases of colon cancer being identified early, when it's easier to treat. Currently, almost half of patients for whom screening is appropriate opt out of colon cancer screening because they view it as too invasive. However, Cologuard samples can be collected at home, and the testing is done at Exact Sciences' labs.

Image source: Exact Sciences.

Now what: In trials, Cologuard detected 92% of colorectal cancers and 42% of advanced adenomas, while FIT detected 74% of cancers and 24% of advanced adenomas.

The new guidelines may also increase the likelihood that doctors will more actively prescribe Cologuard to at-risk patients who refuse a colonoscopy. A positive Cologuard test could help convince patients that a colonoscopy is necessary. 

If doctors increase the pace at which they're prescribing Cologuard, then management may eclipse sales guidance it laid out prior to the guidelines being released.

Exiting the first quarter, management said that sales could climb from less than $40 million last year to $90 million or more this year. If Exact Sciences can over-deliver on that forecast, it would be great news for investors since Exact Sciences is still losing money. Management expects to spend more than twice what it generates in sales this year, so until Exact Sciences' sales translate into profit, investors will need to approach this company cautiously. Having said that, an addressable market valued at $3 billion might make owning Exact Sciences worth the risk. 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. Like this article? Follow him on Twitter where he goes by the handle @ebcapital to see more articles like this. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Stock Quote
Exact Sciences
EXAS
$41.19 (-0.75%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.